Close Menu

Melanoma

News and reporting on melanoma.

The TuPro study will evaluate whether a comprehensive suite of routine and emerging tests can add value to treatment decision making and improve outcomes.  

OncoHost will use the funding to finance clinical trials, open a US location, and prepare to launch its proteomics platform called Prophet.

Early data around an initial composite assay showed it can predict immunooncology drug responses more accurately than tumor mutational burden.

The group aims to determine the feasibility of TROLL-2 and TROLL-3 as diagnostic biomarkers for the prediction of treatment efficacy and prognosis in breast cancer.

The UK-based firm will use the funds to advance its bespoke neoantigen-targeting T-cell therapies for solid cancers including melanoma and NSCLC.

The B44 supertype is associated with improved survival in melanoma patients treated with immunotherapy, but less so in NSCLC patients, due to mutational differences.

Using OneThree's AI platform, Jubilant has identified biomarker-defined cancer indications that it hopes to pursue for JBI-802 in human trials next year.

Researchers showed that ctDNA levels predicted who would respond to first-line immune checkpoint inhibition but were not useful in second-line therapy.

The Phase Ib trial assessed the bespoke cancer vaccine NEO-PV-01 plus Opdivo as a treatment for patients with advanced melanoma, NSCLC, and bladder cancer.

The firm is exploring whether the regimen may work for subgroups of patients with high TMB based on promising signals from the current failed analysis.

Pages